By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — SureGene and Medco Research Institute today announced a pharmacogenomic collaboration to test whether genetic variations can help predict response to widely prescribed antipsychotic drugs.

SureGene and MRI, a wholly-owned subsidiary of Medco Health Solutions, will conduct a prospective study to investigate biomarkers previously identified by SureGene, and validate their utility as predictors of efficacy and safety for drugs prescribed to patients with mental illnesses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.